Announcements Trials
Browse Landscape

Phase

Phase NA 11Phase 3 2Phase 2 2Phase 4 1Phase 1/2 1

Status

Recruiting 5Completed 4Unknown 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 381Breast Neoplasms 364Colorectal Neoplasms 238Stomach Neoplasms 218Carcinoma, Hepatocellular 155Lung Neoplasms 123Neoplasms 120Pancreatic Neoplasms 109Prostatic Neoplasms 100Neoplasm Metastasis 96Recurrence 95Rectal Neoplasms 95Ovarian Neoplasms 90Nasopharyngeal Carcinoma 88Esophageal Neoplasms 82Esophageal Squamous Cell Carcinoma 81Lymphoma, Large B-Cell, Diffuse 79Melanoma 75Small Cell Lung Carcinoma 71Uterine Cervical Neoplasms 70Lymphoma 70Leukemia, Myeloid, Acute 70Brain Neoplasms 69Sarcoma 68Head and Neck Neoplasms 68Squamous Cell Carcinoma of Head and Neck 67Multiple Myeloma 65Carcinoma, Renal Cell 63Triple Negative Breast Neoplasms 61Lymphoma, Non-Hodgkin 53

Interventions

Population Groups 1Hydroxymethylglutaryl-CoA Reductase Inhibitors 1Control Groups 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Heart Failure × Clear all
NCT06092606 2023-10-23

A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients

Monyan Pharmaceutical (Shanghai) Co., Ltd.

Phase 2 Unknown
90 enrolled

Arrhythmias, Cardiac, Heart Failure, Neoplasms

NCT03186404 2022-02-08

SPARE-HF

University Health Network, Toronto

Phase 2 Unknown
112 enrolled

Heart Failure, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡